☆ 4.2 Review

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors

MEDICINA-LITHUANIA (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?

Arshi Khanam et al.

Summary: The incidence of liver cancer, mainly hepatocellular carcinoma (HCC), is increasing. HCC is influenced by the tumor microenvironment and immune mechanisms play a critical role in its development, progression, and metastasis. The initial inflammatory tumor immune microenvironment transitions to an immunosuppressive state, contributing to tumor immune escape. Despite advancements in systemic therapy, HCC prognosis remains poor due to drug resistance, recurrence, and metastasis. Current focus is on new immunotherapeutic strategies to induce effective HCC-specific immune responses and overcome treatment hurdles. This review provides an update on the immunological mechanisms associated with HCC and discusses potential advancements in immunotherapies for HCC treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Gastroenterology & Hepatology

Clinical features and management issues of NAFLD-related HCC: what we know so far

Nicola Pugliese et al.

Summary: Nonalcoholic fatty liver disease (NAFLD) is replacing viral hepatitis as the leading cause of chronic liver disease and hepatocellular carcinoma (HCC) in many Western countries. NAFLD-associated HCC usually affects older patients with multiple comorbidities, frequently develops in the absence of cirrhosis, and is often diagnosed later with worse chance of survival. The worse prognosis is also due to limited surveillance strategies and a lower efficacy of standard treatments.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?

Chao Jiang et al.

Summary: Conversion therapy is an effective strategy to downstage hepatocellular carcinoma (HCC) and increase the chances of liver transplantation (LT). Combining various treatment modalities, including targeted drugs and immunotherapy, has shown promising results in shrinking tumors and benefiting advanced-stage HCC patients. Further research and investigation are needed to fully realize the potential of conversion treatment strategies.

HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2023)

Add to Collection

Article Gastroenterology & Hepatology

Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)

Kiyoshi Hasegawa et al.

Summary: The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma, revised by the Japan Society of Hepatology, was published in October 2021 in Japanese and follows the methodology of evidence-based medicine and the Grading of Recommendations Assessment, Development and Evaluation system. It includes a new algorithm for systemic therapy, considering the availability of multiple drugs for hepatocellular carcinoma. This article provides details on the new or revised algorithms and the evidence behind the recommendations.

HEPATOLOGY RESEARCH (2023)

Add to Collection

Review Biochemistry & Molecular Biology

The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma

Nicolo Brandi et al.

Summary: Immunotherapy combined with locoregional therapies has revolutionized the treatment of advanced HCC by selectively targeting immune cells and enhancing immunity. This combination has the potential to improve patients' outcomes, reduce recurrence rates, and enhance the efficacy of immunotherapy by altering the tumor immune microenvironment. However, many unanswered questions remain regarding the optimal treatment strategies and patient identification for this combined approach.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Gastroenterology & Hepatology

Immunotherapy for hepatocellular carcinoma: Current status and future perspectives

Deepa S. Mandlik et al.

Summary: Hepatocellular carcinoma (HCC) is a deadly and fast-growing tumor. Current treatments for advanced HCC are limited and ineffective. However, immunotherapy has shown promise in treating HCC and provides new treatment options.

WORLD JOURNAL OF GASTROENTEROLOGY (2023)

Add to Collection

Review Oncology

A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy

Alexander Lazzaro et al.

Summary: We reviewed the current approved systemic treatment strategies for advanced hepatocellular carcinoma (HCC), starting from the phase III clinical trial of sorafenib which demonstrated a survival benefit. Despite a period of little progress, there has been a recent explosion of new agents and combinations of agents leading to improved outcomes for patients. We also discussed the authors' current approach to therapy, promising future directions, and important gaps in therapy.

CANCERS (2023)

Add to Collection

Review Medicine, General & Internal

Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings

Annabelle Pan et al.

Summary: Hepatocellular carcinoma (HCC) is a highly lethal cancer worldwide. In resource-limited settings, the majority of HCC cases are diagnosed at an advanced stage with limited treatment options. Even after early detection and resection surgery, HCC recurrence rates are high. Currently, there are no specific biomarkers for HCC recurrence surveillance. Circulating biomarkers can be used to achieve the primary goals of HCC diagnosis and management. This review focuses on circulating blood- or urine-based HCC biomarkers and their potential applications in resource-limited settings where the medical needs for HCC are significant.

DIAGNOSTICS (2023)

Add to Collection

Review Oncology

Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?

Antonella Cammarota et al.

Summary: The treatment landscape of advanced hepatocellular carcinoma (HCC) has become more complex with the introduction of immune checkpoint inhibitors (ICIs). Multikinase inhibitors have emerged as a widespread approach after ICIs, and antiangiogenics may be beneficial for patients with primary resistance to ICIs. The identification of predictive biomarkers and understanding of treatment pathways are urgent matters in HCC research.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Altered Gut Microbiota Composition and Its Potential Association in Patients with Advanced Hepatocellular Carcinoma

Ran Huo et al.

Summary: Hepatocellular carcinoma (HCC) is closely related to dysregulated intestinal microbiota, which can affect the efficacy of immune checkpoint inhibitors. This study investigated the gut microbiota profile in patients with advanced hepatocellular carcinoma, revealing significant differences compared to healthy individuals, including a decrease in butyrate-producing bacteria and an increase in LPS-producing bacteria. Certain bacteria were found to be correlated with biomarkers for liver cancer. These findings provide a basis for using microbiota to regulate immunotherapy, identify potential diagnostic biomarkers, and improve clinical treatment for advanced hepatocellular carcinoma.

CURRENT ONCOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

A Systematic Review and Meta-analysis of Dietary Interventions Modulating Gut Microbiota and Cardiometabolic Diseases-Striving for New Standards in Microbiome Studies

Ilias Attaye et al.

Summary: Dietary interventions can modulate gut microbiota composition, blood pressure, and circulating triglycerides. However, current studies have high methodological heterogeneity and risk of bias. Well-designed and controlled studies are necessary to better understand the complex interaction between diet, microbiome, and cardiometabolic diseases.

GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

Add to Collection

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trail)

Tadatoshi Takayama et al.

Summary: This study compared the survival rates of surgery and RFA for small HCC and found no significant difference between the two treatments.

LIVER CANCER (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC

Qian Song et al.

Summary: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease worldwide due to obesity and metabolic syndrome. Dysbiosis of the gut microbiome and metabolomic changes play a crucial role in the initiation and progression of NAFLD through the gut-liver axis.

BIOMEDICINES (2022)

Add to Collection

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy

Pezhman Shiri et al.

Summary: Angiogenesis is an important scientific subject in the field of malignant tumors, with current research focusing on the role of blood microvessels in cancer cell proliferation, tumor growth, and metastasis. Tyrosine kinases have been identified as therapeutic targets that influence angiogenesis in tumor growth. This review aims to track the advancements in the total synthesis of three receptor tyrosine kinase inhibitors and examines the purification process of these anticancer medicines. Notably, different patents may report varying procedures and yields for the synthesis of the desired drugs and their intermediates.

MOLECULAR DIVERSITY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges

Yu-Xian Teng et al.

Summary: The global prevalence of metabolic diseases has led to an increase in NAFLD and NAFLD-related HCC. Risk factors for NAFLD-related HCC include age, gender, metabolic comorbidities, unhealthy lifestyle habits, lack of exercise, genetic susceptibility, liver fibrosis, and degree of cirrhosis. Prevention measures include low-calorie diet, moderate-intensity exercise, treatment of metabolic comorbidities, smoking and alcohol cessation, and screening for HCC in patients with advanced NAFLD-related fibrosis or cirrhosis.

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2022)

Add to Collection

Article Oncology

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma

Pei-Chang Lee et al.

Summary: This study found that the gut microbiome and bile acids are associated with the treatment outcomes of HCC patients receiving ICI therapy, with a microbial signature of Lachnoclostridium enrichment and Prevotella 9 depletion significantly predicting treatment efficacy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma

Masatoshi Kudo

HEPATOBILIARY SURGERY AND NUTRITION (2022)

Add to Collection

Review Immunology

Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings

Bhrigu Kumar Das

Summary: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide and is associated with liver damage caused by factors such as hepatitis virus infection and alcohol consumption. Increasing evidence suggests that gut microbes play a role in cancer development, and the interaction between gut microbes and the liver has a significant impact on liver disease and HCC progression. Research has shown that maintaining gut microbial flora through therapeutic interventions such as probiotics, prebiotics, and antibiotics can help reduce HCC-associated symptoms.

APMIS (2022)

Add to Collection

Review Oncology

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives

Maria Pallozzi et al.

Summary: The search for non-invasive biomarkers is crucial in modern oncology to evaluate patients' response to immunotherapy. The treatment perspectives of hepatocellular carcinoma (HCC) have significantly improved after the introduction of immunotherapy, but only a small portion of patients benefit from it. Therefore, finding accurate biomarkers to predict prognosis has become a hot topic of research.

CANCERS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma

Francesca Romana Ponziani et al.

Summary: This study suggests that the composition of the gut microbiota and the level of intestinal inflammation are associated with the response to immune therapy in patients with hepatocellular carcinoma (HCC). The intestinal environment also changes dynamically during treatment.

HEPATOLOGY COMMUNICATIONS (2022)

Add to Collection

Review Gastroenterology & Hepatology

Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges

Yu-Xian Teng et al.

Summary: The global prevalence of NAFLD-related HCC is increasing, with 25% of the global population suffering from NAFLD. Key strategies for preventing NAFLD-related HCC include low-calorie diet, exercise, cessation of unhealthy habits, and treatment of metabolic comorbidities.

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Erez N. Baruch et al.

Summary: This study conducted a phase 1 clinical trial and found that FMT treatment in patients with anti-PD-1-refractory metastatic melanoma, along with reinduction of anti-PD-1 immunotherapy, resulted in clinical responses in some patients. This suggests that modulating the gut microbiota could be a promising approach in cancer treatment.

SCIENCE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients

Min-Woo Chung et al.

Summary: This study collected fecal samples from advanced HCC patients treated with nivolumab and found that responders had higher gut bacterial diversity compared to non-responders. The study also identified specific bacterial taxa associated with therapeutic response in HCC patients. Additionally, certain bacterial ratios and species were proposed as predictive markers for response to nivolumab in HCC treatment.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Review Immunology

Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis

Ziniu Ding et al.

Summary: Viral etiology may not serve as a selection criteria for patients receiving ICIs in HCC, and viral status has limited impact on TIME remodeling during HCC tumorigenesis.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers

Jinzhu Mao et al.

Summary: This study investigated the relationship between gut microbiome and clinical response to anti-PD-1 immunotherapy in patients with advanced hepatobiliary cancers. Taxonomic signatures enriched in responders were effective biomarkers to predict the clinical response and survival benefit of immunotherapy. Functional annotation indicated that taxa associated with different metabolic pathways may modulate the clinical response to immunotherapy in hepatobiliary cancers.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Health Care Sciences & Services

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma

Alessandro Granito et al.

Summary: This study found that post-treatment transient transaminase elevation could predict the objective response to superselective cTACE, providing a simple tool for guiding treatment strategy in HCC patients in clinical practice.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Oncology

The Role of the Microbiome in Liver Cancer

Mar Moreno-Gonzalez et al.

Summary: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a major cause of cancer-related deaths globally. Increasing evidence shows that changes in intestinal microbiota composition and function are associated with HCC progression, contributing to liver cirrhosis and inflammatory responses. Therapeutic strategies involving modification of the microbiome have shown potential in reducing inflammation and fibrosis in chronic liver disease and HCC.

CANCERS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)

Philipp K. Haber et al.

Summary: A review of 49 high-quality phase III randomized controlled trials in hepatocellular carcinoma conducted between 2002 and 2020 found that 9 had positive results, suggesting that immunotherapies may be more effective in viral etiologies.

GASTROENTEROLOGY (2021)

Add to Collection

Meeting Abstract Oncology

IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).

Michel Ducreux et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Robin Kate Kelley et al.

Summary: This study evaluated the treatment regimens for patients with hepatocellular carcinoma and found that all regimens were tolerable and clinically active, with the T300 + D regimen showing the most favorable benefit-risk profile. Early expansion of CD8+ lymphocytes was associated with treatment response across arms.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma

Betul Gok Yavuz et al.

Summary: Understanding biomarkers that predict clinical response in hepatocellular carcinoma immunotherapy is crucial for improving patient selection and maximizing clinical benefits. Various biomarkers from tumoral tissues and peripheral blood have been studied, with potential for further mathematical biomarkers yet to be explored in HCC.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

Add to Collection

Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis

Paramita Dasgupta et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma

Won Jin Ho et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article

Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment

Amblessed E. Onuma et al.

GENE EXPRESSION (2020)

Add to Collection

Article Oncology

Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update

Jessica P. Hwang et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors A Chinese population-based study

Lili Li et al.

MEDICINE (2020)

Add to Collection

Meeting Abstract Oncology

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Thomas Yau et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Advances in cancer immunotherapy 2019-latest trends

Stephan Kruger et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

Add to Collection

Review Gastroenterology & Hepatology

Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma

Clifford Akateh et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Article Oncology

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma

Marina Ruiz de Galarreta et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Oncology

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma

Yi Zheng et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Review Oncology

Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice

Edoardo G. Giannini et al.

CANCERS (2019)

Add to Collection

Review Oncology

Fecal microbiota transplantation in cancer management: Current status and perspectives

Danfeng Chen et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

Add to Collection

Article Multidisciplinary Sciences

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy et al.

SCIENCE (2018)

Add to Collection

Review Oncology

Mechanisms of resistance to immune checkpoint inhibitors

Russell W. Jenkins et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

Add to Collection

Review Gastroenterology & Hepatology

Targets for immunotherapy of liver cancer

Tim F. Greten et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells

Chi Ma et al.

SCIENCE (2018)

Add to Collection

Article

Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice

Shoji Yamada et al.

Oncotarget (2018)

Add to Collection

Article Oncology

Monitoring immune checkpoint regulators as Predictive Biomarkers in hepatocellular carcinoma

Ritu Shrestha et al.

FRONTIERS IN ONCOLOGY (2018)

Add to Collection

Article Immunology

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

Suzanne George et al.

IMMUNITY (2017)

Add to Collection

Article Medicine, General & Internal

Effect of Oral Capsule-vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection A Randomized Clinical Trial

Dina Kao et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Add to Collection

Article Gastroenterology & Hepatology

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

Austin G. Duffy et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

Add to Collection

Article Oncology

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valerie Vilgrain et al.

LANCET ONCOLOGY (2017)

Add to Collection

Review Biochemistry & Molecular Biology

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies

Galina Khemlina et al.

MOLECULAR CANCER (2017)

Add to Collection

Article Oncology

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Scott Gettinger et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Oncology

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

Hae Il Jung et al.

CANCER RESEARCH AND TREATMENT (2017)

Add to Collection

Article Immunology

Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma

Hyeyoon Chang et al.

APMIS (2017)

Add to Collection

Correction Biochemistry & Molecular Biology

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (vol 165, pg 35, 2016)

Willy Hugo et al.

CELL (2017)

Add to Collection

Review Immunology

Coinhibitory Pathways in Immunotherapy for Cancer

Susanne H. Baumeister et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Jianjun Gao et al.

CELL (2016)

Add to Collection

Review Gastroenterology & Hepatology

Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment

Ender Gunes Yegin et al.

HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2016)

Add to Collection

Article Gastroenterology & Hepatology

Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features

Julien Calderaro et al.

HEPATOLOGY (2016)

Add to Collection

Article Gastroenterology & Hepatology

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Jorge A. Marrero et al.

JOURNAL OF HEPATOLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Stefani Spranger et al.

NATURE (2015)

Add to Collection

Article Immunology

Weight Gain After Fecal Microbiota Transplantation

Neha Alang et al.

OPEN FORUM INFECTIOUS DISEASES (2015)

Add to Collection

Review Gastroenterology & Hepatology

Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections

Christina M. Surawicz et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)

Add to Collection

Article Gastroenterology & Hepatology

Epidemiology of Hepatocellular Carcinoma Consider the Population

Sahil Mittal et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)

Add to Collection

Article Immunology

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Tyler R. Simpson et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2013)

Add to Collection

Article Gastroenterology & Hepatology

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

Bruno Sangro et al.

JOURNAL OF HEPATOLOGY (2013)

Add to Collection

Article Gastroenterology & Hepatology

Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma

Alessandro Cucchetti et al.

JOURNAL OF HEPATOLOGY (2013)

Add to Collection

Article Oncology

Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4

Dianne H. Dapito et al.

CANCER CELL (2012)

Add to Collection

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

Add to Collection

Review Surgery

Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma

L. Tiong et al.

BRITISH JOURNAL OF SURGERY (2011)

Add to Collection

Article Oncology

Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors

Shin Foong Ngiow et al.

CANCER RESEARCH (2011)

Add to Collection

Article Gastroenterology & Hepatology

Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma

Bao-Ju Wang et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2011)

Add to Collection

Article Gastroenterology & Hepatology

Endotoxin Accumulation Prevents Carcinogen-Induced Apoptosis and Promotes Liver Tumorigenesis in Rodents

Le-Xing Yu et al.

HEPATOLOGY (2010)

Add to Collection

Review Gastroenterology & Hepatology

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

Riccardo Lencioni et al.

SEMINARS IN LIVER DISEASE (2010)

Add to Collection

Article Oncology

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

Qiang Gao et al.

CLINICAL CANCER RESEARCH (2009)

Add to Collection

Article Immunology

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Karl S. Peggs et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

Add to Collection

Article Oncology

Interaction of B7-H1 on Intrahepatic Cholangiocarcinoma Cells With PD-1 on Tumor-Infiltrating T Cells as a Mechanism of Immune Evasion

Yufu Ye et al.

JOURNAL OF SURGICAL ONCOLOGY (2009)

Add to Collection

Article Oncology

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann-Lii Cheng et al.

LANCET ONCOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Multidisciplinary Sciences

CTLA-4 control over Foxp3+ regulatory T cell function

Kajsa Wing et al.

SCIENCE (2008)

Add to Collection

Article Immunology

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

Manish J. Butte et al.

IMMUNITY (2007)

Add to Collection

Article Multidisciplinary Sciences

Reversal of the TCR stop signal by CTLA-4

Helga Schneider et al.

SCIENCE (2006)

Add to Collection

Article Oncology

Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice

Carsten T. Viehl et al.

ANNALS OF SURGICAL ONCOLOGY (2006)

Add to Collection

Article Medicine, Research & Experimental

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

Sergio A. Quezada et al.

JOURNAL OF CLINICAL INVESTIGATION (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.